“Cocaine abuse and dependence pose significant challenges in the U.S., yet there is no FDA-approved treatment for cocaine intoxication, a life-threatening condition marked by symptoms such as agitation, hyperthermia, tachycardia, arrhythmias, hypertensive crisis, myocardial infarction, stroke, and seizures. In 2022, cocaine-related overdose deaths reached 27,569. With around 505,000 emergency room visits annually involving cocaine use and approximately 61,000 of these requiring detox services for cocaine overdose, TNX-1300 could potentially reduce the morbidity and mortality associated with cocaine intoxication. By addressing the root cause rather than just the symptoms, TNX-1300 may offer substantial advantages over the current standard of care for cocaine overdose.”
Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals